search
Back to results

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (LILAC-TIMI 76)

Primary Purpose

Atrial Fibrillation (AF)

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Abelacimab
Placebo
Sponsored by
Anthos Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation (AF) focused on measuring abelacimab, randomized, placebo-controlled, double-blind, endpoint evaluation, atrial fibrillation

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient is able to understand and willing to provide written informed consent to participate in the trial Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording) Age 65-74 and a CHA2DS2VASc ≥5 OR age ≥75 and a CHA2DS2VASc ≥4 Judged by the responsible physician or by their own decision to be unsuitable for oral anticoagulation At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls Exclusion Criteria: AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use) Patients who received warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban within 60 days prior to randomization Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study Other protocol defined Inclusion/Exclusion criteria may apply

Sites / Locations

  • Anthos Investigative Site 1040Recruiting
  • Anthos Investigative Site 1041Recruiting
  • Anthos Investigative Site 1077Recruiting
  • Anthos Investigative Site 1015Recruiting
  • Anthos Investigative Site 1070Recruiting
  • Anthos Investigative Site 1071Recruiting
  • Anthos Investigative Site 1049
  • Anthos Investigative Site 1012Recruiting
  • Anthos Investigative Site 1013Recruiting
  • Anthos Investigative Site 1025Recruiting
  • Anthos Investigative Site 1022Recruiting
  • Anthos Investigative Site 1019Recruiting
  • Anthos Investigative Site 1008
  • Anthos Investigative Site 1072Recruiting
  • Anthos Investigative Site 1067Recruiting
  • Anthos Investigative Site 1026Recruiting
  • Anthos Investigative Site 1002Recruiting
  • Anthos Investigative Site 1004Recruiting
  • Anthos Investigative Site 1044Recruiting
  • Anthos Investigative Site 1046Recruiting
  • Anthos Investigative Site 1052Recruiting
  • Anthos Investigative Site 1033Recruiting
  • Anthos Investigative Site 1042Recruiting
  • Anthos Investigative Site 1003Recruiting
  • Anthos Investigative Site 1030Recruiting
  • Anthos Investigative Site 1016Recruiting
  • Anthos Investigative Site 1006Recruiting
  • Anthos Investigative Site 1043Recruiting
  • Anthos Investigative Site 1054Recruiting
  • Anthos Investigative Site 1039Recruiting
  • Anthos Investigative Site 1023Recruiting
  • Anthos Investigative Site 1028Recruiting
  • Anthos Investigative Site 1082Recruiting
  • Anthos Investigative Site 1021Recruiting
  • Anthos Investigative Site 1059Recruiting
  • Anthos Investigative Site 1080Recruiting
  • Anthos Investigative Site 1066Recruiting
  • Anthos Investigative Site 1036Recruiting
  • Anthos Investigative Site 1014Recruiting
  • Anthos Investigative Site 1037Recruiting
  • Anthos Investigative Site 1065Recruiting
  • Anthos Investigative Site 1005Recruiting
  • Anthos Investigative Site 1048Recruiting
  • Anthos Investigative Site 1035Recruiting
  • Anthos Investigative Site 1001
  • Anthos Investigative Site 1032Recruiting
  • Anthos Investigative Site 1050Recruiting
  • Anthos Investigative Site 1057Recruiting
  • Anthos Investigative Site 1056Recruiting
  • Anthos Investigative Site 1069Recruiting
  • Anthos Investigative Site 1068Recruiting
  • Anthos Investigative Site 1053Recruiting
  • Anthos Investigative Site 1064Recruiting
  • Anthos Investigative Site 1063Recruiting
  • Anthos Investigative Site 1079Recruiting
  • Anthos Investigative Site 1024Recruiting
  • Anthos Investigative Site 1085Recruiting
  • Anthos Investigative Site 1011Recruiting
  • Anthos Investigative Site 1060Recruiting
  • Anthos Investigative Site 1084Recruiting
  • Anthos Investigative Site 1031Recruiting
  • Anthos Investigative Site 1029Recruiting
  • Anthos Investigative Site 1038Recruiting
  • Anthos Investigative Site 1034Recruiting
  • Anthos Investigative Site 1018Recruiting
  • Anthos Investigative Site 1010
  • Anthos Investigative Site 1009Recruiting
  • Anthos Investigative Site 1073Recruiting
  • Anthos Investigative Site 1501Recruiting
  • Anthos Investigative Site 1503Recruiting
  • Anthos Investigative Site 1529Recruiting
  • Anthos Investigative Site 2012Recruiting
  • Anthos Investigative Site 2003Recruiting
  • Anthos Investigative Site 2010Recruiting
  • Anthos Investigative Site 2005Recruiting
  • Anthos Investigative Site 2004Recruiting
  • Anthos Investigative Site 2002Recruiting
  • Anthos Investigative Site 2006Recruiting
  • Anthos Investigative Site 1801Recruiting
  • Anthos Investigative Site 1205Recruiting
  • Anthos Investigative Site 1201Recruiting
  • Anthos Investigative Site 1209Recruiting
  • Anthos Investigative Site 1204Recruiting
  • Anthos Investigative Site 1202Recruiting
  • Anthos Investigative Site 1207Recruiting
  • Anthos Investigative Site 1203Recruiting
  • Anthos Investigative Site 1208Recruiting
  • Anthos Investigative Site 1908Recruiting
  • Anthos Investigative Site 1902Recruiting
  • Anthos Investigative Site 1920Recruiting
  • Anthos Investigative Site 1910Recruiting
  • Anthos Investigative Site 1906Recruiting
  • Anthos Investigative Site 1911Recruiting
  • Anthos Investigative Site 1912Recruiting
  • Anthos Investigative Site 1921Recruiting
  • Anthos Investigative Site 1915Recruiting
  • Anthos Investigative Site 1903Recruiting
  • Anthos Investigative Site 1907Recruiting
  • Anthos Investigative Site 1922Recruiting
  • Anthos Investigative Site 1904Recruiting
  • Anthos Investigative Site 1913Recruiting
  • Anthos Investigative Site 1914Recruiting
  • Anthos Investigative Site 1909Recruiting
  • Anthos Investigative Site 1901Recruiting
  • Anthos Investigative Site 1917Recruiting
  • Anthos Investigative Site 1918Recruiting
  • Anthos Investigative Site 1919Recruiting
  • Anthos Investigative Site 1916Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Abelacimab (MAA868)

Placebo

Arm Description

Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.

Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.

Outcomes

Primary Outcome Measures

Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)
Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding

Secondary Outcome Measures

Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia
Abelacimab versus placebo with regard to the composite of ischemic stroke, SE, MI, VTE, or acute limb ischemia
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event
Efficacy: Cardiovascular (CV) mortality
Efficacy: All-cause mortality
Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Abelacimab versus placebo with regard to net clinical outcome defined as the composite of ischemic stroke, SE, MI, VTE, acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding

Full Information

First Posted
January 12, 2023
Last Updated
October 17, 2023
Sponsor
Anthos Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05712200
Brief Title
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Acronym
LILAC-TIMI 76
Official Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 27, 2022 (Actual)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Anthos Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation (AF)
Keywords
abelacimab, randomized, placebo-controlled, double-blind, endpoint evaluation, atrial fibrillation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1900 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Abelacimab (MAA868)
Arm Type
Experimental
Arm Description
Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly.
Intervention Type
Biological
Intervention Name(s)
Abelacimab
Other Intervention Name(s)
MAA868
Intervention Description
Abelacimab provided as liquid in vial (150 mg/mL)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Dosage Formulation: Liquid (in vial) Dose Strength: Placebo to Abelacimab
Primary Outcome Measure Information:
Title
Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)
Time Frame
Up to 30 months
Title
Safety: Time to first occurrence of Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding
Time Frame
Up to 30 months
Secondary Outcome Measure Information:
Title
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), or acute limb ischemia
Description
Abelacimab versus placebo with regard to the composite of ischemic stroke, SE, MI, VTE, or acute limb ischemia
Time Frame
Up to 30 months
Title
Efficacy: Time to first event of ischemic stroke, systemic embolism (SE), or Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding event
Time Frame
Up to 30 months
Title
Efficacy: Cardiovascular (CV) mortality
Time Frame
Up to 30 months
Title
Efficacy: All-cause mortality
Time Frame
Up to 30 months
Title
Time to first event of ischemic stroke, systemic embolism (SE), myocardial infarctions (MI), venous thromboembolism (VTE), acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Description
Abelacimab versus placebo with regard to net clinical outcome defined as the composite of ischemic stroke, SE, MI, VTE, acute limb ischemia, or International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Time Frame
Up to 30 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is able to understand and willing to provide written informed consent to participate in the trial Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording) Age 65-74 and a CHA2DS2VASc ≥5 OR age ≥75 and a CHA2DS2VASc ≥4 Judged by the responsible physician or by their own decision to be unsuitable for oral anticoagulation At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls Exclusion Criteria: AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use) Patients who received warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban within 60 days prior to randomization Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study Other protocol defined Inclusion/Exclusion criteria may apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Janeen Salter
Phone
+1 617 430 6957
Email
Janeen.s@anthostherapeutics.com
Facility Information:
Facility Name
Anthos Investigative Site 1040
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1041
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36608
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1077
City
Los Angeles
State/Province
California
ZIP/Postal Code
90022
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1015
City
Northridge
State/Province
California
ZIP/Postal Code
91325
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1070
City
Redding
State/Province
California
ZIP/Postal Code
96001
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1071
City
San Dimas
State/Province
California
ZIP/Postal Code
91773
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1049
City
Denver
State/Province
Colorado
ZIP/Postal Code
80218
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Anthos Investigative Site 1012
City
Stamford
State/Province
Connecticut
ZIP/Postal Code
06905
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1013
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1025
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1022
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33777
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1019
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32114
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1008
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Individual Site Status
Withdrawn
Facility Name
Anthos Investigative Site 1072
City
Miami Lakes
State/Province
Florida
ZIP/Postal Code
33016
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1067
City
Ormond Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1026
City
Safety Harbor
State/Province
Florida
ZIP/Postal Code
34695
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1002
City
Saint Augustine
State/Province
Florida
ZIP/Postal Code
32086
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1004
City
Saint Augustine
State/Province
Florida
ZIP/Postal Code
32086
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1044
City
Tamarac
State/Province
Florida
ZIP/Postal Code
33321
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1046
City
Tampa
State/Province
Florida
ZIP/Postal Code
33625
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1052
City
Lithonia
State/Province
Georgia
ZIP/Postal Code
30058
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1033
City
Macon
State/Province
Georgia
ZIP/Postal Code
31201
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1042
City
Norcross
State/Province
Georgia
ZIP/Postal Code
30092
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1003
City
Suwanee
State/Province
Georgia
ZIP/Postal Code
30024
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1030
City
Park Ridge
State/Province
Illinois
ZIP/Postal Code
60068
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1016
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67207
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1006
City
Alexandria
State/Province
Louisiana
ZIP/Postal Code
71301
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1043
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1054
City
Bangor
State/Province
Maine
ZIP/Postal Code
04401
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1039
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21218
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1023
City
Lanham
State/Province
Maryland
ZIP/Postal Code
20746
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1028
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1082
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02124
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1021
City
Lansing
State/Province
Michigan
ZIP/Postal Code
48912
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1059
City
Southgate
State/Province
Michigan
ZIP/Postal Code
48195
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1080
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64151
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1066
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1036
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1014
City
Middletown
State/Province
New York
ZIP/Postal Code
10941
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1037
City
Rosedale
State/Province
New York
ZIP/Postal Code
11422
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1065
City
Cary
State/Province
North Carolina
ZIP/Postal Code
27518
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1005
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1048
City
Fayetteville
State/Province
North Carolina
ZIP/Postal Code
28314
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1035
City
Henderson
State/Province
North Carolina
ZIP/Postal Code
28792
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1001
City
Lenoir
State/Province
North Carolina
ZIP/Postal Code
28638
Country
United States
Individual Site Status
Withdrawn
Facility Name
Anthos Investigative Site 1032
City
Rock Hill
State/Province
South Carolina
ZIP/Postal Code
29732
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1050
City
Elizabethton
State/Province
Tennessee
ZIP/Postal Code
37643
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1057
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1056
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38128
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1069
City
Houston
State/Province
Texas
ZIP/Postal Code
77002
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1068
City
Houston
State/Province
Texas
ZIP/Postal Code
77025
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1053
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1064
City
Houston
State/Province
Texas
ZIP/Postal Code
77084
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1063
City
McAllen
State/Province
Texas
ZIP/Postal Code
78503
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1079
City
McKinney
State/Province
Texas
ZIP/Postal Code
75071
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1024
City
Odessa
State/Province
Texas
ZIP/Postal Code
79761
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1085
City
Port Arthur
State/Province
Texas
ZIP/Postal Code
77642
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1011
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1060
City
Waco
State/Province
Texas
ZIP/Postal Code
76712
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1084
City
American Fork
State/Province
Utah
ZIP/Postal Code
84003
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1031
City
Bountiful
State/Province
Utah
ZIP/Postal Code
84010
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1029
City
Holladay
State/Province
Utah
ZIP/Postal Code
84117
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1038
City
Pleasant View
State/Province
Utah
ZIP/Postal Code
84404
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1034
City
Roy
State/Province
Utah
ZIP/Postal Code
84067
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1018
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1010
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20109
Country
United States
Individual Site Status
Withdrawn
Facility Name
Anthos Investigative Site 1009
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24014
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1073
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1501
City
Campina Grande Do Sul
ZIP/Postal Code
83430
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1503
City
Campinas
ZIP/Postal Code
13010
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1529
City
São Paulo
ZIP/Postal Code
05403
Country
Brazil
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2012
City
Mira Road
State/Province
Nova Scotia
ZIP/Postal Code
B1M DA1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2003
City
Cambridge
State/Province
Ontario
ZIP/Postal Code
N1R 7R1
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2010
City
Sherbrooke
State/Province
Quebec
ZIP/Postal Code
J1H 5N4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2005
City
Halifax
ZIP/Postal Code
B3H 3A7
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2004
City
New Westminster
ZIP/Postal Code
V3L 3W4
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2002
City
Québec
ZIP/Postal Code
G1R 2J6
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 2006
City
Saint-Jérôme
ZIP/Postal Code
J7Z 5T3
Country
Canada
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1801
City
Hangzhou
ZIP/Postal Code
310009
Country
China
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1205
City
Ashkelon
ZIP/Postal Code
7827804
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1201
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1209
City
H̱olon
ZIP/Postal Code
58100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1204
City
Kfar Saba
ZIP/Postal Code
44281
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1202
City
Nahariya
ZIP/Postal Code
22100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1207
City
Petah tikva
ZIP/Postal Code
49100
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1203
City
Reẖovot
ZIP/Postal Code
7610001
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1208
City
Zefat
ZIP/Postal Code
13110
Country
Israel
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1908
City
Chikushino-shi
ZIP/Postal Code
818-8516
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1902
City
Chuo-Ku
ZIP/Postal Code
103-0027
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1920
City
Funabashi-Shi
ZIP/Postal Code
273-8588
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1910
City
Hamada-shi
ZIP/Postal Code
697-8511
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1906
City
Himeji-Shi
ZIP/Postal Code
670-0836
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1911
City
Imabari-shi
ZIP/Postal Code
799-1502
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1912
City
Isehara-Shi
ZIP/Postal Code
259-1193
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1921
City
Koto-Ku
ZIP/Postal Code
135-0061
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1915
City
Kure-shi
ZIP/Postal Code
737-8505
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1903
City
Matsumoto-Shi
ZIP/Postal Code
390-8621
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1907
City
Nagano-Shi
ZIP/Postal Code
380-0814
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1922
City
Sapporo-shi
ZIP/Postal Code
063-0005
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1904
City
Sendai-shi
ZIP/Postal Code
983-8520
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1913
City
Shimonoseki-shi
ZIP/Postal Code
752-8510
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1914
City
Tachikawa-shi
ZIP/Postal Code
190-0014
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1909
City
Tochigi
ZIP/Postal Code
321-0293
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1901
City
Urayasu
ZIP/Postal Code
279-0001
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1917
City
Uwajima-Shi
ZIP/Postal Code
798-8510
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1918
City
Yokohama-shi
ZIP/Postal Code
232-0024
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1919
City
Yokohama-Shi
ZIP/Postal Code
236-0037
Country
Japan
Individual Site Status
Recruiting
Facility Name
Anthos Investigative Site 1916
City
Yokohama-Shi
ZIP/Postal Code
245-8575
Country
Japan
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

We'll reach out to this number within 24 hrs